Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements review identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://charlesc962jyq6.ourcodeblog.com/profile